HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

TECH

Bio-Techne Corporation (S&P 500)

Healthcare — Biotechnology

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. Its Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Hold 2.8 / 5 10 analysts
$72.40
$-0.07 (-0.10%)
Target: $70.50 (-2.6%)

Price History

52-Week Range
Sign in to add TECH to a watchlist or set price alerts.

Fundamentals

Market Cap$11.35B
P/E Ratio (TTM)62.41
Forward P/E31.31
EPS (TTM)$1.16
Dividend Yield0.44%
Profit Margin14.97%
Revenue Growth1.30%
ROE9.03%
Debt/Equity13.71
Recommendation Hold 2.8
Analyst Target$70.50
Analysts10
Next Earnings Aug 12, 2026 BMO
Indexes S&P 500

Technical Indicators

RSI (14)63.5
Beta1.28
SMA 20$72.39
SMA 40$72.34
52-Week High$72.69
52-Week Low$43.20
50-Day Avg$72.25
200-Day Avg$61.90
Avg Volume$3.34M
Volume$2.71M

Performance Analysis

NEUTRAL

TECH presents a mixed picture with both positive and negative indicators.

- Trading near its 52-week high ($72.69), which may indicate limited upside.
+ RSI at 63.5 shows positive momentum.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
- P/E of 62.4 is elevated — the market expects high growth or it may be overvalued.
~ Modest revenue growth of 1.3% year-over-year.
~ Wall Street consensus is "Hold" from 10 analysts.
- Average analyst target of $70.50 implies 2.6% downside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Oct 01, 2026 21:01 UTC

Back to Screener Export Report